INHIBIKASE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.66 USD | -4.05% |
|
-8.29% | +30.71% |
| 06-05 | Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline | CI |
| 05-21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
Presenter SpeechMilton Werner (Executives)Well, thank you, everyone, for joining the live webc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinsonâs disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinsonâs disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinsonâs-related disorders of the brain and GI tract, orphan indications related to Parkinsonâs disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Companyâs RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Calendar
09:00pm
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.66
USD
Average target price
15.5
USD
Spread / Average Target
+833.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.71% | 12.44M | |
| +55.55% | 59.34B | |
| +43.17% | 40.24B | |
| -4.71% | 39.88B | |
| -5.56% | 28.55B | |
| +13.76% | 27.26B | |
| -22.00% | 19.23B | |
| +31.50% | 12.61B | |
| +2.16% | 12.49B | |
| +25.70% | 12.28B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Transcript : Inhibikase Therapeutics, Inc. - Special Call